Blaze Bioscience Stock

Blaze Bioscience develops and commercializes products that assist surgeons to treat cancer patients.

Sign up today and learn more about Blaze Bioscience Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Blaze Bioscience Stock

Blaze Bioscience is a Seattle-based, privately-held biotechnology company dedicated to developing products that assist surgeons in their quest to improve the lives of cancer patients. The company was founded in 2010 to develop and commercialize the Tumor Paint technology. Tumor Paint provides real-time, highresolution intraoperative visualization of cancer cells, enabling better detection and more complete and precise surgical resection of cancer. The first Tumor Paint product candidate, which is a combination of a targeting peptide and a fluorescent beacon, is under development for multiple solid tumors.

Funding History

June 2012$6.4M
June 2015$9.7M
April 2016$0
October 2017$16.1M
May 2018$3.0M



James Olson

President & CEO

Heather Franklin

Senior Director of Process Development & Manufacturing

Claudia Jochheim

Vice President, Research & Project Management

Julia Novak

Vice President, Finance & Operations

Mila Lobanova


sec - Apr, 14 2020


EquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.

Some data provided by Crunchbase

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As: